Skip to content
GHIAA Logo Small
Envelope Linkedin-in Twitter
  • Home
  • Our Work
    • Consulting
    • Glossary
    • MAPGuide
    • Vaccine Manufacturing
  • About
    • About GHIAA
    • Team
  • News
    • GHIAA News
    • Newsletter
  • Contact
  • search
Menu
  • Home
  • Our Work
    • Consulting
    • Glossary
    • MAPGuide
    • Vaccine Manufacturing
  • About
    • About GHIAA
    • Team
  • News
    • GHIAA News
    • Newsletter
  • Contact
  • search
 
search

Shionogi – GARDP, Cefiderocol License Agreement

  • Post author:GHIAA Admin
  • Post published:July 8, 2022
  • Post category:

Continue ReadingShionogi – GARDP, Cefiderocol License Agreement

Shionogi – GARDP, Cefiderocol License Agreement

  • Post author:GHIAA Admin
  • Post published:July 8, 2022
  • Post category:

Continue ReadingShionogi – GARDP, Cefiderocol License Agreement

Shionogi – GARDP, Cefiderocol License Agreement

  • Post author:GHIAA Admin
  • Post published:July 8, 2022
  • Post category:

Continue ReadingShionogi – GARDP, Cefiderocol License Agreement

Shionogi – GARDP, Cefiderocol License Agreement

  • Post author:GHIAA Admin
  • Post published:July 8, 2022
  • Post category:

Continue ReadingShionogi – GARDP, Cefiderocol License Agreement

Shionogi – GARDP, Cefiderocol License Agreement

  • Post author:GHIAA Admin
  • Post published:July 8, 2022
  • Post category:

Continue ReadingShionogi – GARDP, Cefiderocol License Agreement

Shionogi – GARDP, Cefiderocol License Agreement

  • Post author:GHIAA Admin
  • Post published:July 8, 2022
  • Post category:

Continue ReadingShionogi – GARDP, Cefiderocol License Agreement

Shionogi – GARDP, Cefiderocol License Agreement

  • Post author:GHIAA Admin
  • Post published:July 8, 2022
  • Post category:

Continue ReadingShionogi – GARDP, Cefiderocol License Agreement

MPP – BMS Sublicense & Tech Transfer Agreement

  • Post author:Loren
  • Post published:May 23, 2020
  • Post category:

Continue ReadingMPP – BMS Sublicense & Tech Transfer Agreement

MPP – BMS – Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue ReadingMPP – BMS – Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
  • 1
  • 2
  • Go to the next page

Recent Posts

  • MAPGuide Glossary (DRAFT)
  • Key Terms of Alliance Agreements

Recent Comments

    Archives

    • May 2020

    Categories

    • Resource & Analysis

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact Us

    Get In Touch

    comms@ghiaa.org

    Tel: 919-419-0300
    919-906-4818
    Fax: 919-419-8833

    Attn: Executive Director
    GHIAA
    PO Box 14713
    Research Triangle Park, NC 27709, USA

    Browse

    Our Work
    MAPGuide
    About GHIAA
    Team
    News
    Useful Links

    Contact Us

    Get In Touch

    info@ghiaa.org

    Tel: 919-419-0300
    919-906-4818
    Fax: 919-419-8833

    Attn: Executive Director
    GHIAA
    PO Box 14713
    Research Triangle Park, NC 27709, USA

    Browse

    GHIAA
    MAPGuide
    About GHIAA
    Team
    News
    Links
    COVID19

     

    Twitter Linkedin-in
    comms@ghiaa.org

    Privacy Policy

    • Privacy Policy
    • Join
    Menu
    • Privacy Policy
    • Join

    © 2023 Global Healthcare Innovation Alliance Accelerator. All Rights Reserved

    Sign Up to Our Newsletter

    Receive updates about GHIAA’s latest tools, resources and news.

    I consent to receiving email updates from GHIAA and have read and agree to the Privacy Policy and Terms of Service..

    Agreement Type

    • Any Agreement Types
    • Contract Manufacturing
    • License
    • Other
    • R&D Collaboration
    • R&D Funding
    • Supply/Purchase
    • Technology Transfer

    Select Partner Type

    • Any Partner types
    • Academic institution
    • Funder
    • Government
    • Industry
    • Multilateral organization
    • Product development partnership

    Select Development Stage

    • Any Develoment stages
    • Discovery/Concept
    • Preclinical
    • Early clinical (through Phase 2)
    • Late clinical (Phase 3)
    • Commercialization
    • Field Testing

    Select Technology

    • Any Technologies
    • Device
    • Diagnostic
    • Drug
    • Vaccine

    Select Issue or Sub-issues

    • Equitable Access
      • All Equitable Access
      • Donation
      • Ensuring continuity
      • Access plans & principles
      • Preparedness & response
      • Affordable pricing
      • Territory access commitments
    • Business model
      • All Business model
      • Benefit sharing
      • Regulatory strategy
      • Governance
      • Payment Structures
      • Product supply
    • Protecting & sharing information
      • All Protecting & sharing information
      • Confidentiality
      • Information sharing
      • Publication of Results
      • Technology transfer
    • Intellectual Property
      • All Intellectual Property
      • License Grants
      • Ownership of IP
      • Protection of IP
    • Liability
      • All Liability
      • Indemnification & liability
      • Insurance
      • Representations & Warranties
    • Term & termination
      • All Term & termination
      • Effects of termination
      • Term of agreement
      • Termination & withdrawal